Sharemaestro Newsreel

Cormorant Asset Management (RLYB) now reports 0% beneficial ownership of Rallybio

Cormorant Asset Management, LP and Bihua Chen have reported that they no longer beneficially own any shares of Rallybio Corp (RLYB), marking their ownership at 0%. This disclosure, filed as an amendment to a Schedule 13G, indicates zero sole or shared voting or dispositive …

Genmab A/S (GMAB): Orbis and Allan Gray report 5.3% beneficial ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly reported a beneficial ownership stake of 5.3% in Genmab A/S (GMAB), totaling 3,328,505 Ordinary Shares. This includes both direct Ordinary Shares and American Depositary Shares (ADS). The filing indicates that while they …

(PRAX) and the Role of Price-Sensitive Allocations

This article provides a detailed AI-driven analysis of Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting a strong overweight bias across all time horizons. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report …

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …

Vistagen (VTGN) narrows quarterly loss, eyes FDA path after mixed fasedienol data

Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …

Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure

A group of affiliated Susquehanna entities has filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 3,339,231 Ordinary Shares, representing 4.8% of uniQure N.V.'s outstanding shares. This stake includes options to buy shares held by Susquehanna Securities, LLC and SIG Brokerage, LP. …

TransMedics Group, Inc. Investor News: Rosen Law Firm

The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm is encouraging shareholders of TransMedics Group to visit its website or contact them for more information regarding …

OPKO Health (NASDAQ:OPK) Trading Down 5.4% - Here's What Happened

OPKO Health (NASDAQ:OPK) shares experienced a 5.4% drop in mid-day trading, closing at $1.325 with significantly lower trading volume than average. Despite the stock decline, the company recently reported better-than-expected quarterly earnings, with an adjusted loss of $0.01 per share against an anticipated $0.08 …

Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake

Cormorant Asset Management, LP and Bihua Chen have disclosed a 4.35% beneficial ownership stake in MoonLake Immunotherapeutics (MLTX), totaling 3,205,433 Class A ordinary shares. This stake, reported via a SCHEDULE 13G/A filing, indicates shared voting and dispositive power over the shares and is based …

Innovative Eyewear Inc Q2 2026: Revenue $1.01M, EPS $(0.26) — 10-Q Summary

Innovative Eyewear Inc (LUCY) reported Q2 2026 results showing a significant revenue increase to $1.01M, a 74% year-over-year rise, driven by strong unit volume and expanded retail presence. The company also narrowed its net loss to $1.67M from $2.11M in Q2 2025, with diluted …

Butterfly Network Stock (BFLY) Opinions on Q2 Earnings and Institutional Interest

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVie's neuroscience franchise experienced strong growth in the first half of 2026, with sales reaching $6.1 billion, driven by key drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, and the rapid uptake of Vyalev. The company anticipates further growth from the potential approval of …

Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves

Brandes Investment Partners reports 14.9% Utah Medical Products (UTMD) stake

Gilead wins appeals court ruling against overseas drug imports

A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40

This article provides a quick overview of analyst ratings for Kura Oncology (KURA.US), noting a forecast price range of $23 to $40. It indicates that the company is currently receiving a 'Buy' rating from analysts, reflecting positive sentiment. The information is presented as a …

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

Novavax Inc. stock underperforms Friday when compared to competitors

Novavax Inc. (NVAX) shares dropped 1.11% on Friday, closing at $8.05, despite a three-day winning streak being snapped. This underperformance occurred on a negative trading day for the broader market, with both the NASDAQ Composite and Dow Jones Industrial Average also experiencing declines.

Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates

Molina Healthcare Inc. stock outperforms competitors on strong trading day

Molina Healthcare Inc. (MOH) stock rose by 3.27% to $212.43 on a generally down day for the market, outperforming both the S&P 500 and Dow Jones Industrial Average. The company's stock closed 13.25% below its 52-week high achieved in July.

VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates

Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build

VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus

August 2026's Promising Penny Stocks

This article highlights three promising penny stocks for August 2026: Nephros (NEPH), Siebert Financial (SIEB), and Douglas Elliman (DOUG). It examines their financial health, recent performance, and strategic initiatives, noting that these companies offer potential for growth despite being smaller or newer entities. The …

Insulet Corp. stock outperforms competitors despite losses on the day

Insulet Corp. (PODD) stock fell by 2.12% to $143.34 on Friday, breaking a six-day winning streak, despite a broader market decline with the S&P 500 and Dow Jones also experiencing losses. The company's stock still managed to outperform its competitors, even with the daily …

Align Technology Inc. stock outperforms competitors on strong trading day

Align Technology Inc. (ALGN) saw its stock rise by 2.90% to $181.31, outperforming a generally down market where both the S&P 500 Index and Dow Jones Industrial Average experienced slight declines. This marked the third consecutive day of gains for the company's stock.

Oscar Health Inc Stock (OSCR) Moved Up by 7.22% on Aug 14: What Investors Need To Know

Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds

Investment entities affiliated with Squadron Capital Management LLC have reported a beneficial ownership of 7.0% in Relmada Therapeutics, Inc. This stake, amounting to 7,350,000 shares, is held by Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank, based on shares …

Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure

Biomea Fusion (NASDAQ:BMEA) is attracting renewed market interest due to increased institutional investment. The company, a clinical-stage biopharmaceutical firm focusing on precision therapies for cancer and metabolic diseases, sees its outlook driven by clinical execution, regulatory progress, and financial management. Its strategy centers on …

Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A

Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank have filed an amended Schedule 13G (Amendment No. 4) for Traws Pharma (TRAW), reporting 0% beneficial ownership. The group now holds no shares of Traws Pharma common stock and possesses no …

King Street Capital discloses 4.6% Surgery Partners (SGRY) holding in Schedule 13G

King Street Capital Management, L.P., along with King Street Capital Management GP, L.L.C., and Brian J. Higgins, have reported a joint beneficial ownership of 6,058,141 shares of Surgery Partners, Inc. (SGRY) common stock. This holding represents 4.6% of the company's outstanding shares, based on …

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …

Solventum Corp. stock rises Friday, outperforms market

Solventum Corp. (SOLV) stock increased by 2.46% to $88.59 on Friday, marking its third consecutive day of gains. This rise occurred during a generally negative trading session where the S&P 500 Index (SPX) fell 0.17% and the Dow Jones Industrial Average (DJIA) fell 0.20%, …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 2,192,980 shares of Elutia Inc. (ELUT) Class A common stock, representing a 4.9% stake. This disclosure, made via an amended Schedule 13G filing, indicates shared voting and dispositive power over these …

Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High‑Risk COVID Market

Pfizer Inc. has completed a real-world study in Korea on Paxlovid, demonstrating its effectiveness in older adults within long-term care hospitals against severe COVID-19, mortality, and decline in daily function. This observational study, which compared Paxlovid users to non-users matched on various factors, supports …